EP Patent

EP1904052A1 — Liquid pharmaceutical formulations of docetaxel

Assigned to Hospira Australia Pty Ltd · Expires 2008-04-02 · 18y expired

What this patent protects

There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter readin…

USPTO Abstract

There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter reading in the range of from 2.5 to 7.

Drugs covered by this patent

Patent Metadata

Patent number
EP1904052A1
Jurisdiction
EP
Classification
—
Expires
2008-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Hospira Australia Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.